Stephen H. Willard
Stephen H. Willard's purchase track record
Stephen H. Willard has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/16/2022 | NRXP | $59K | -38.3% | -54.8% | +14.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership. Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.
Transaction History
| LGVN | ▼ Sell | Tax Withholding | 1,987 | $5K | 10/1/2026 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 18,046 | $13K | 7/1/2026 | View on chart |
| LGVN | ▲ Buy | Grant | 500,000 | $0 | 5/1/2026 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 4,740 | $5K | 4/1/2026 | View on chart |
| LGVN | ▲ Buy | Grant | 200,000 | $0 | 3/2/2026 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 105,533 | $58K | 3/2/2026 | View on chart |
| LGVN | ▲ Buy | Grant | 200,000 | $0 | 3/2/2026 | View on chart |
| NRXP | ▲ Buy | Open Market | 50,000 | $59K | 12/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Longeveron to speak at three longevity investment conferences
Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.
Longeveron to speak at three longevity investment conferences. Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.